TEVA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

4.39B

+3.72%

0.656

-7.57%

4.01B

+3.07%

0.579

+11.35%

4.21B

+0.86%

0.647

-1.94%

Estimates Revision

The market is revising Upward the revenue expectations for Teva Pharmaceutical Industries Limited (TEVA) for FY2025, with the revenue forecasts being adjusted by 0.38% over the past three months. During the same period, the stock price has changed by 63.76%.

Revenue Estimates for FY2025

Revise Upward

+0.38%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.43%

In Past 3 Month

Stock Price

Go Up

+63.76%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast TEVA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 29.25 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 30.100

Low

28.00

Averages

29.25

High

32.00

Current: 30.100

Low

28.00

Averages

29.25

High

32.00

BofA

Buy

maintain

$29 -> $32

2025-12-09

Reason

BofA

Price Target

$29 -> $32

2025-12-09

maintain

Buy

Reason

BofA raised the firm's price target on Teva to $32 from $29 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm's CNS Therapeutics Conference.

Goldman Sachs

Matt Dellatorre

Buy

maintain

$28 -> $31

2025-12-08

Reason

Goldman Sachs

Matt Dellatorre

Price Target

$28 -> $31

2025-12-08

maintain

Buy

Reason

Goldman Sachs analyst Matt Dellatorre raised the firm's price target on Teva to $31 from $28 and keeps a Buy rating on the shares. The recently published IRA-negotiated price for Austedo, which will go into effect in 2027, was better than expected, and management has reiterated their FY27+ guidance for the product, the analyst tells investors in a research note. Goldman sees the company as capable of long-term mid-single digit EBITDA growth, driven by both topline execution and margin expansion, and no major upcoming losses-of-exclusivity.

Barclays

Overweight

initiated

$35

2025-12-08

Reason

Barclays

Price Target

$35

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of Teva with an Overweight rating and $35 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

Scotiabank

initiated

$35

2025-12-04

Reason

Scotiabank

Price Target

$35

2025-12-04

initiated

Reason

Scotiabank initiated coverage of Teva with an Outperform rating and $35 price target.

JPMorgan

Chris Schott

Overweight

maintain

$26 -> $28

2025-11-06

Reason

JPMorgan

Chris Schott

Price Target

$26 -> $28

2025-11-06

maintain

Overweight

Reason

JPMorgan analyst Chris Schott raised the firm's price target on Teva to $28 from $26 and keeps an Overweight rating on the shares. The company reported solid Q3 results, the analyst tells investors in a research note.

Goldman Sachs

Matt Dellatorre

Buy

maintain

$25 -> $28

2025-11-06

Reason

Goldman Sachs

Matt Dellatorre

Price Target

$25 -> $28

2025-11-06

maintain

Buy

Reason

Goldman Sachs analyst Matt Dellatorre raised the firm's price target on Teva to $28 from $25 and keeps a Buy rating on the shares.

Valuation Metrics

The current forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA.N) is 11.68, compared to its 5-year average forward P/E of 4.73. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

4.73

Current PE

11.68

Overvalued PE

6.55

Undervalued PE

2.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

6.94

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

7.54

Undervalued EV/EBITDA

6.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.87

Current PS

0.00

Overvalued PS

1.16

Undervalued PS

0.57

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TEVA News & Events

Events Timeline

No data

News

4.5

12-16SeekingAlpha

Immuneering Set to Join the Nasdaq Biotechnology Index

4.5

12-15NASDAQ.COM

SPYM, DRKY: Significant Inflows into ETFs

3.0

12-13Yahoo Finance

Is Teva's 80% Increase in 2024 Already Reflecting Its Potential for Recovery?

People Also Watch

Frequently Asked Questions

What is Teva Pharmaceutical Industries Ltd (TEVA) stock price today?

The current price of TEVA is 30.1 USD — it has decreased -0.1 % in the last trading day.

What is Teva Pharmaceutical Industries Ltd (TEVA)'s business?

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

What is the price predicton of TEVA Stock?

What is Teva Pharmaceutical Industries Ltd (TEVA)'s revenue for the last quarter?

Teva Pharmaceutical Industries Ltd revenue for the last quarter amounts to 4.48B USD, increased 3.42 % YoY.

What is Teva Pharmaceutical Industries Ltd (TEVA)'s earnings per share (EPS) for the last quarter?

Teva Pharmaceutical Industries Ltd. EPS for the last quarter amounts to 0.37 USD, decreased -194.87 % YoY.

What changes have occurred in the market's expectations for Teva Pharmaceutical Industries Ltd (TEVA)'s fundamentals?

How many employees does Teva Pharmaceutical Industries Ltd (TEVA). have?

Teva Pharmaceutical Industries Ltd (TEVA) has 33892 emplpoyees as of December 17 2025.

What is Teva Pharmaceutical Industries Ltd (TEVA) market cap?

Today TEVA has the market capitalization of 34.53B USD.